Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIb open-label study of nilotinib in newly diagnosed Ph+ or BCR-ABL+ CML in chronic phase
2009-017775-19Phase 3Completed
- Sponsor
- Novartis
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nilotinib in chronic myelogenous leukemia (CML), sponsored by Novartis. Primary endpoint: Complete molecular response at 18 months. Started Mar 2010; status: completed.
02
Drugs
nilotinib
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2009-017775-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017775-19.